Skip to content

Catalyst Pharmaceutical CPRX Accrued Liabilities, Current

Accrued Liabilities, Current at other companies

Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
Scholar Rock logo
Scholar RockSRRK
Arrowhead Research logo
Arrowhead ResearchARWR
ALN
Alnylam PharmaceuticalsALNY
Cytokinetics logo
CytokineticsCYTK

Other financials

Income statement

See full
Revenue$149.4M+5.6%
Gross profit$134.9M+9.2%
Operating income$73.2M+15.6%
Net income$63.7M+12.3%
EPS (diluted)$0.50+11.1%

Balance sheet

See full
Cash & equivalents$755.9M+30.2%
Total debt$2.7M-13.3%
Total equity$1.0B+27.5%
Total assets$1.1B+26.3%

Cash flow

See full
Operating cash flow$59.6M-0.8%
CapEx$27.0K
Free cash flow$59.6M-0.8%

Valuation

See full
Market cap$3.84B+2.7%
Enterprise value$3.09B-4.1%
P/E17.4×-1.6×
P/S6.4×-0.6×

Profitability

See full
Gross margin86%-0.2pp
Operating margin44.8%+1.6pp
Net margin37.1%+0.2pp
FCF margin34.9%-15.2pp

Returns & leverage

See full
Return on equity24.5%-4.6pp
Debt / equity0.0×
Current ratio7.1×+1.0×

Where this comes from

Reported directly by Catalyst Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Catalyst Pharmaceutical's accrued liabilities, current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Catalyst Pharmaceutical's accrued liabilities, current?
Catalyst Pharmaceutical (CPRX) reported accrued liabilities, current of $125.25M in Q1 2026.
How has Catalyst Pharmaceutical's accrued liabilities, current changed year-over-year?
Catalyst Pharmaceutical's accrued liabilities, current increased by 24.7% year-over-year, from $100.45M to $125.25M.
What is the long-term trend for Catalyst Pharmaceutical's accrued liabilities, current?
Over 5 years (2020 to 2025), Catalyst Pharmaceutical's accrued liabilities, current has grown at a 49.0% compound annual growth rate (CAGR), from $18.5M to $135.95M.